The CDTI Innovation invests, together with NARA HEALTH CAPITAL (RCF) in MIMARK DIAGNOSTICS, which is carrying out an innovative project focusing on the diagnosis of The Uterus cancer (EC)
Its approach is based on the creation of a solution of in vitro diagnosis (IVD) combined with an analysis algorithm
The CDTI Innovation, through itsInnvierte programmetogether with NARA HEALTH CAPITAL (RCF), has reached an agreement with the partners of MIMARK DIAGNOSTICS, S.L., to enter the capital of the company. The input committed by the CDTI Innovation is 270,000 euros.
MiMARK Diagnostics S.Lmission is to transform the gynaecological diagnosis thanks to the implementation of the gynaecological fluids as a new biopsy and as a source of biomarkers. The gynaecological fluids allow the company to carry out a minimally invasive approach for the diagnosis of gynaecological diseases with clinical needs not covered, as these represent very specifically to the surrounding tissues gynaecological bodies concerned.
The first product of the company is WomEC, a test of in vitro diagnosis to the uterus cancer that is based on the analysis of several proteins in soluble fractions of a sample of uterine aspired and in a diagnostic algorithm. The endometrial cancer is the first gynaecological cancers in developed countries, with more than 6,700 new cases per year in Spain. The diagnosis in women that have an abnormal vaginal bleeding, but only 1 in 10 will have a diagnosis of cancer of the uterus. Today the diagnosis requires, in a large number of women, the realization of a biopsy guided by histeroscopia, invasive procedure and high cost that could be saved in many cases with WomEC.
NARA HEALTH CAPITAL (RCF)
Nara Capitalmanagement is a dedicated to private capital investment in biotech and processing digital health, and in initial stages of development.
It is in being deeply apalanca sectoral specialization to support startups that generate long-term value their investors and create a positive impact, improving the health and quality of life of patients and of society.
CDTI Innovation
The CDTI innovation is the agency of the ministry of science and innovation that supports innovation based on knowledge, advice and providing public funding for innovation through subsidies or aid partly refundable for innovation and managing public procurement, pre-commercial.
Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. To date, the CDTI, through Innvierte, has committed more than 390 M €in 20 investment vehicles that have invested in more than 240 companies, and through its joint investment line directly committed an amount exceeding 300 M €in more than 124 enterprises. ”
The CDTI Innovation also facilitates the internationalization of business projects of r & D and innovation of spanish companies and entities and manages the participation of spanish companies in international r & D, Horizon and Eureka, Europe and in industries of science and space.
The centre for technological development and innovation, E.P.E. (CDTI) is a public entity under the ministry of Science and innovation.
More information:
Office of the press
prensa@cdti.es
91-581.55.00
On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
On Twitter:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial